MedTrace Logo

A Study of GLWL-01 in Patients With Prader-Willi Syndrome

NCT03274856 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2020-03-27

Study results available
· View outcomes & findings →

Summary

The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the treatment of patients with Prader-Willi Syndrome (PWS).

Conditions

Interventions

DRUG

GLWL-01

Oral administration of 3 capsules, twice a day

DRUG

Placebo

Oral administration of 3 capsules, twice a day

Sponsors & Collaborators

  • GLWL Research Inc.

    lead OTHER

Principal Investigators

  • Study Director · GLWL Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2019-06-12
Completion
2019-06-12
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03274856 on ClinicalTrials.gov